

Tesamorelin

Abdominal Fat Study

- Cognitive improvements from using Tesamorlin
- 1-year study
- HIV+ with abdominal fat 40 y/o
- Spanish or English
- Multiple In-person screening visits
- Immediate group or delayed group
- Daily Text messaging
- Self-administer medication for 6 months
- 5 study visits, plus phone visits
- Compensation up to \$635 w/ optional LPs

Participate Today

Are you HIV positive?

Do you have abdominal fat?

Why not participate in a study examining the potential benefits of Egrifta® on the brain?

Participate in Research

Lab results (at no cost to you)

Monetary compensation up to \$550

What is Egrifta®?

- ▶ Injectable prescription medication
- ▶ Contains growth hormone-releasing factor
- ▶ Reduces excess abdominal fat in HIV-infected individuals with lipodystrophy

Who May Qualify: *

- ▶ HIV Positive with abdominal fat
- ▶ Ages 40 and up
- ▶ Currently on stable antiretroviral therapy
- ▶ Willing to do MRIs

Free 6 months supply of Egrifta®

*Not all individuals eligible to participate.

(619) 543-5000
hnrp.hivresearch.edu
220 Dickinson Street, Suite B • San Diego, California 92103-8231

HNRP
HIV NEUROBEHAVIORAL RESEARCH PROGRAM
hnrp.hivresearch.ucsd.edu